Verification of questionable information about the COVID-19 vaccines
DOI:
https://doi.org/10.51094/jxiv.1428キーワード:
COVID-19、 mRNA vaccines、 Self-amplifying RNA vaccines、 DNA contamination、 Genomic integration、 Vaccine safety抄録
Since the rollout of large-scale COVID-19 vaccination programs, misinformation has often been disseminated through social media, particularly regarding mRNA vaccines. Even scientists have sometimes exacerbated the problem and undermined public trust in health policies by proposing questionable theories. In this study, we present experimental and statistical analyses that address these claims. Animal experiments were conducted to evaluate the hypothesis that self-amplifying RNA vaccines can replicate and spread between individuals, a theory that our findings strongly refute. We also examined the claim that the presence of DNA contamination in mRNA vaccine formulations leads to the integration of DNA fragments into the genome, thereby altering gene function or expression to induce various adverse events, a theory that is also refuted by our findings. Additionally, we conducted statistical comparisons between mRNA and conventional influenza vaccines, challenging the narrative promoted by mainstream scientists and physicians that mRNA vaccines are categorically safer. Our findings underscore the need for scientists to rigorously investigate and transparently communicate about such claims, thereby helping to rebuild public trust in vaccination efforts.
利益相反に関する開示
The authors declare no conflict of interests exist.ダウンロード *前日までの集計結果を表示します
引用文献
Comes JDG, Pijlman GP, Hick TAH. Rise of the RNA machines - self-amplification in mRNA vaccine design. Trends Biotechnol 2023 Nov;41(11):1417-1429. doi: 10.1016/j.tibtech.2023.05.007.
https://www.arabnews.jp/en/japan/article_129340/
https://www.europarl.europa.eu/doceo/document/P-10-2025-000048_EN.html
https://www.jiji.com/jc/article?k=2024122500785&g=soc
Ogata AF, Cheng CA, Desjardins M, Senussi Y, Sherman AC, Powell M, Novack L, Von S, Li X, Baden LR, Walt DR. Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients. Clin Infect Dis. 2022 74(4):715-718. doi: 10.1093/cid/ciab465.
Low JG, de Alwis R, Chen S, Kalimuddin S, Leong YS, Mah TKL, Yuen N, Tan HC, Zhang SL, Sim JXY, Chan YFZ, Syenina A, Yee JX, Ong EZ, Sekulovich R, Sullivan BB, Lindert K, Sullivan SM, Chivukula P, Hughes SG, Ooi EE. A phase I/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine. NPJ Vaccines. 2022 Dec 13;7(1):161. doi: 10.1038/s41541-022-00590-x.
Oda Y, Kumagai Y, Kanai M, Iwama Y, Okura I, Minamida T, Yagi Y, Kurosawa T, Greener B, Zhang Y, Walson JL. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet Infect Dis. 2024 Apr;24(4):351-360. doi: 10.1016/S1473-3099(23)00650-3.
Hồ NT, Hughes SG, Ta VT, Phan LT, Đỗ Q, Nguyễn TV, Phạm ATV, Thị Ngọc Đặng M, Nguyễn LV, Trịnh QV, Phạm HN, Chử MV, Nguyễn TT, Lương QC, Tường Lê VT, Nguyễn TV, Trần LT, Thi Van Luu A, Nguyen AN, Nguyen NT, Vu HS, Edelman JM, Parker S, Sullivan B, Sullivan S, Ruan Q, Clemente B, Luk B, Lindert K, Berdieva D, Murphy K, Sekulovich R, Greener B, Smolenov I, Chivukula P, Nguyễn VT, Nguyen XH. Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials. Nat Commun. 2024 May 14;15(1):4081. doi: 10.1038/s41467-024-47905-1.
A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults. https://clinicaltrials.gov/study/NCT04668339
Krumholz HM, Wu Y, Sawano M, Shah R, Zhou T, Arun AS, Khosla P, Kaleem S, Vashist A, Bhattacharjee B, Ding Q, Lu Y, Caraballo C, Warner F, Huang C, Herrin J, Putrino D, Hertz D, Dressen B, Iwasaki A. Post-Vaccination Syndrome: A Descriptive Analysis of Reported Symptoms and Patient Experiences After Covid-19 Immunization. medRxiv [Preprint]. 2023 Nov 10:2023.11.09.23298266. doi: 10.1101/2023.11.09.23298266.
Grady CB, Bhattacharjee B, Silva J, Jaycox J, Lee LW, Silva Monteiro V, Sawano M, Massey D, Caraballo C, Gehlhausen JR, Tabachnikova A, Mao T, Lucas C, Peña-Hernandez MA, Xu L, Tzeng TJ, Takahashi T, Herrin J, Güthe DB, Akrami A, Assaf G, Davis H, Harris K, McCorkell L, Schulz WL, Griffin D, Wei H, Ring AM, Guan L, Dela Cruz C, Krumholz HM, Iwasaki A. Impact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve individuals with Long COVID. Commun Med (Lond). 2025 May 9;5(1):163. doi: 10.1038/s43856-025-00829-3.
McKernan K, Helbert Y, Kane LT, McLaughlin S. Sequencing of bivalent Moderna and Pfizer mRNA vaccines reveals nanogram to microgram quantities of expression vector dsDNA per dose. OSFPreprints, https://osf.io/preprints/osf/b9t7m_v1
Igyártó BZ, Qin Z. The mRNA-LNP vaccines - the good, the bad and the ugly? Front Immunol. 2024 Feb 8;15:1336906. doi: 10.3389/fimmu.2024.1336906.
Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018 Apr;17(4):261-279. doi: 10.1038/nrd.2017.243.
König B, Kirchner JO. Methodological Considerations Regarding the Quantification of DNA Impurities in the COVID-19 mRNA Vaccine Comirnaty. Methods Protoc. 2024 May 8;7(3):41. doi: 10.3390/mps7030041.
Wang, TJ, Kim A, Kim K. A rapid detection method of replication-competent plasmid DNA from COVID-19 mRNA vaccines for quality control. J High School Sci. 2024; 8 (4): 427–439.
Kaiser S, Kaiser S, Reis J, Marschalek R. Quantification of objective concentrations of DNA impurities in mRNA vaccines. Vaccine. 2025 May 10;55:127022. doi: 10.1016/j.vaccine.2025.127022.
Speicher DJ, Rose J, Gutschi M, Wiseman DM, McKernan K. DNA fragments detected in monovalent and bivalent Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada: Exploratory dose response relationship with serious adverse events. OSFPreprints, https://osf.io/preprints/osf/mjc97_v1
Yang H. Establishing acceptable limits of residual DNA. PDA J Pharm Sci Technol. 2013 Mar-Apr;67(2):155-63. doi: 10.5731/pdajpst.2013.00910.
Results of deliberations by the Disease and Disability Certification Review Board (Infectious Disease and Vaccination Review Subcommittee, COVID-19 Vaccination Health Damage Review Division 1) , Ministry of Health, Labour and Welfare. July 23, 2025 (in Japanese) [accessed Jul. 26, 2025] https://www.mhlw.go.jp/content/10900000/001522098.pdf
Parry PI, Lefringhausen A, Turni C, Neil CJ, Cosford R, Hudson NJ, Gillespie J. 'Spikeopathy': COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA. Biomedicines. 2023 Aug 17;11(8):2287. doi: 10.3390/biomedicines11082287.
Kakeya H, Nitta T, Kamijima Y, Miyazawa T. Significant Increase in Excess Deaths after Repeated COVID-19 Vaccination in Japan. JMA J. 2025 Apr 28;8(2):584-586. doi: 10.31662/jmaj.2024-0298.
ダウンロード
公開済
投稿日時: 2025-08-06 09:10:31 UTC
公開日時: 2025-09-11 07:32:52 UTC
ライセンス
Copyright(c)2025
Takeshi Nitta
Taku Kashiyama
Yoshihisa Matsumoto
Tetsuya Toyoda
Takayuki Miyazawa
Yukari Kamijima
Kakeya, Hideki

この作品は、Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licenseの下でライセンスされています。